 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...

Athira Pharma to Participate in Upcoming October Conferences

Athira Pharma, Inc. (NASDAQ:ATHA  Get Free Report) was the recipient of a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling 996,000 shares, a decrease of 16.3% from the July 31st total of 1,190,000 shares. Currently, 2.8% ...

Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Down 16.3% in August

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Athira Pharma (ATHA Research Report), with a pric... In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Athira Pharma (ATHA &#8211...

Mizuho Securities Sticks to Its Buy Rating for Athira Pharma (ATHA)

Athira Pharma (NASDAQ:ATHA  Free Report) had its price target trimmed by JMP Securities from $20.00 to $19.00 in a report released on Friday, MarketBeat Ratings reports. The firm currently has...

Athira Pharma (NASDAQ:ATHA) PT Lowered to $19.00 at JMP Securities

Athira Pharma GAAP EPS of -$0.78 beats by $0.02

Completed end of Phase 2 meeting and continued engagement with U.S. Food and Drug AdministrationAppointed Andrew Gengos as Chief Financial Officer and Chief Business OfficerMaintains strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key ...

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

New preclinical data demonstrate neuroprotective effects of fosgonimeton in models of amyloid--mediated toxicity In preclinical models, ATH-1105 protects against pathologies common to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) Data presented at the Alzheimers Association ...

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Three poster presentations to highlight clinical and preclinical data across Athiras pipeline of neuroprotective therapeutic candidatesBOTHELL, Wash., July 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small ...

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

Athira Pharma, Inc. (NASDAQ:ATHA  Get Rating) insider Andrew Gengos purchased 15,000 shares of the stock in a transaction that occurred on Wednesday, June 7th. The stock was bought at an average cost of $3.43 per share, with a total value of $51,450.00. Following the completion of the ...

Insider Buying: Athira Pharma, Inc. (NASDAQ:ATHA) Insider Buys $51,450.00 in Stock

Athira Pharma, Inc. (NASDAQ:ATHA Get Rating) insider Andrew Gengos purchased 15,000 shares of the companys stock in a transaction dated Wednesday, June 7th. The shares were acquired at an average price of $3.43 per share, with a total value of $51,450.00. Following the transaction, the insider now ...

Insider Buying: Athira Pharma, Inc. (NASDAQ:ATHA) Insider Buys 15,000 Shares of Stock

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Watchers	2,174
52-Wk Low	$1.86
52-Wk High	$4.41

Market Cap	$76.87M
Volume (M)	119,336.00
52-Wk High	$4.41
52-Wk Low	$1.86

ATHA Athira Pharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals